Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista de la Sociedad Española del Dolor
versión impresa ISSN 1134-8046
Resumen
MOYA RIERA, J.; MURILLO GONZALEZ, M.; RODRIGUEZ MESA, D. y ESCOBAR ALVAREZ, Y.. Fentanyl for breakthrough cancer pain. Rev. Soc. Esp. Dolor [online]. 2013, vol.20, n.3, pp.137-141. ISSN 1134-8046. https://dx.doi.org/10.4321/S1134-80462013000300006.
Pain control is an important aspect in the quality of the healthcare. The drug of choice in breakthrough pain control requires potency and a very fast rate of absorption. This speed is a critical aspect. The preparations of fentanyl, because of its great potency, probably are drugs that the clinician should use in patients with breakthrough pain, but not all fentanyl preparations have similar kinetics. The pharmacokinetic properties of fentanyl buccal tablets (FBT) powered by OraVescent® drug delivery technology have shown great speed of absorption, much faster than other preparations of opiates. There is evidence indicating that the preparation of FBT fentanyl is effective in episodes of cancer breakthrough pain. Fentanyl FTB has also shown efficacy in breakthrough pain not related to cancer.
Palabras clave : Fentanyl; Breakthrough pain; Cancer.